RESUMEN
Gemcitabine is indicated for the treatment of nonmicrocytic lung, breast, pancreatic, bladder and ovarian cancer. Mild dyspnea has been reported but the incidence of severe lung damage is low. We report the case of a 58-year-old woman diagnosed with locally advanced infiltrating ductal carcinoma of the breast who received gemcitabine as part of neoadjuvant chemotherapy and suffered from severe pulmonary toxicity. We reviewed the cases published in the literature and conclude that although Gemcitabine is generally well tolerated, pulmonary toxicity requires high level of suspicion and prompt treatment to prevent an unfavourable outcome (AU)
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Carcinoma/tratamiento farmacológico , Neoplasias de la Mama/patología , Neoplasias de la Mama , Carcinoma/patología , Carcinoma , Fumar/efectos adversos , Tomografía por Rayos X/métodos , Tomografía por Rayos XRESUMEN
Propósito: Descripción de un caso de adenocarcinomade endometrio precoz, con un comportamientoatípico.Material y métodos: Describimos el caso deun adenocarcinoma de endometrio típico precoz ycon buen pronóstico (Ib) con un comportamientoevolutivo atípico, que tras un período de latencia,nos llevó a la sospecha de otro tumor primario, conrespuesta favorable a un esquema citostático concarboplatino y paclitaxel, que hoy sabemos que esactivo en los tumores malignos de endometrio.Discusión: Estadíos iniciales de neoplasias endometrialescomo la de nuestra paciente tienen unosíndices de supervivencia entre el 80-90%, siendoinusual el aparecer una recidiva con un período librede enfermedad tan prolongado
Purpose: To describe a case of endometrialcarcinoma with an atypical outcome.Material and methods: We report a typicalearly endometrial adenocarcinoma with a goodprognosis, which after a long latent period showedan atypical outcome with the appearance of a lungtumour suspicious to be another primary tumour.However, a good response was obtained treatingwith carboplatin and paclitaxel, known as an activechemotherapy of endometrial neoplasms.Discussion: Early endometrial tumours havesurvival rates between 80 and 90%. It is unusual thedevelopment of progression after a long diseasefreeperiod
